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OBJECTIVE—In the general, nondiabetic population, fasting
glucose increases only slightly over time, whereas 2-h postload
glucose shows a much steeper age-related rise. The reasons
underlying these different age trajectories are unknown. We
investigated whether common genetic variants associated with
fasting and 2-h glucose contribute to age-related changes of these
traits.
RESEARCH DESIGN AND METHODS—We studied 5,196
nondiabetic participants of the Whitehall II cohort (aged 40–78
years) attending up to four 5-yearly oral glucose tolerance tests.
A genetic score was calculated separately for fasting and 2-h
glucose, including 16 and 5 single nucleotide polymorphisms, re-
spectively. Longitudinal modeling with age centered at 55 years
was used to study the effects of each genotype and genetic score
on fasting and 2-h glucose and their interactions with age, adjust-
ing for sex and time-varying BMI.
RESULTS—The fasting glucose genetic score was signiﬁcantly
associated with fasting glucose with a 0.029 mmol/L (95% CI
0.023–0.034) difference (P = 2.76 3 10
221) per genetic score
point, an association that remained constant over time (age in-
teraction P = 0.17). Two-hour glucose levels differed by 0.076
mmol/L (0.047–0.105) per genetic score point (P = 3.1 3 10
27);
notably, this effect became stronger with increasing age by 0.006
mmol/L (0.003–0.009) per genetic score point per year (age in-
teraction P = 3.0 3 10
25), resulting in diverging age trajectories
by genetic score.
CONCLUSIONS—Common genetic variants contribute to the
age-related rise of 2-h glucose levels, whereas associations of
variants for fasting glucose are constant over time, in line with
stable age trajectories of fasting glucose. Diabetes 60:1617–
1623, 2011
E
arlier longitudinal analyses of participants of the
Whitehall II cohort have demonstrated a gradual
and a subsequent steep increase in both fasting
and postload glucose preceding the diagnosis of
type 2 diabetes (1). This lends some support to a multi-
stage model of diabetes etiology in which a compensatory
and adaptive phase is followed by a period of b-cell de-
compensation that leads to a rapid rise in glucose levels
and ultimately overt diabetes (2). In contrast, in the gen-
eral, nondiabetic population, fasting glucose levels in-
crease only slightly over time (3), whereas 2-h postload
glucose shows a much steeper age-related rise (1), an ef-
fect that appears to be less pronounced at younger ages
(4). The reasons underlying these different age trajectories
of fasting and postload glucose in nondiabetic individuals
are not well understood.
Because of the recent progress in genetic mapping, our
understanding of the genetic basis of glycemic control in
nondiabetic individuals has rapidly increased. Genome-
wide associated studies (GWASs) using cross-sectional
phenotypic data have now identiﬁed 16 loci associated
with fasting and 5 loci associated with postchallenge glu-
cose levels (5–11). Some of these loci were known or have
been shown subsequently to also be associated with the
risk of type 2 diabetes in independent case-control studies.
Common genetic variants associated with fasting and 2-h
glucose may contribute to age-related changes of these
traits; however, this has not been investigated because
genetic studies generally rely on a single glucose mea-
surement or oral glucose tolerance test (OGTT) and thus
are unable to investigate associations of genetic loci with
changes in fasting and postload glucose levels over time or
with increasing age.
We therefore set out to investigate longitudinally the
inﬂuence of recently identiﬁed common genetic loci re-
lated to glucose metabolism in nondiabetic individuals, as
well as derived genetic risk scores (10,11), on age-related
changes of fasting and 2-h glucose over a maximum of 18
years of follow-up in the prospective Whitehall II study,
using data from 5,196 participants aged 40–78 years who
attended up to four 5-yearly clinic visits (13,141 glucose
measurements or OGTTs).
RESEARCH DESIGN AND METHODS
All nonindustrial civil servants aged 35–55 years working in the London ofﬁces
of 20 departments were invited to participate in the longitudinal Whitehall II
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ORIGINAL ARTICLEstudy. A total of 10,308 (6,895 men) subjects were recruited between 1985 and
1988 (phase 1) and followed at eight subsequent phases ~2.5 years apart (12).
Every phase included a questionnaire, and every second phase additionally
included a clinical examination (phases 1, 3, 5, 7, and 9). Participation in
subsequent clinical phases, deﬁned as either a returned questionnaire or clinic
attendance, was 6,057 men and 2,758 women at phase 3 (1991–1993); 5,473
men and 2,397 women at phase 5 (1997–1999); 4,893 men and 2,074 women at
phase 7 (2002–2004); and 4,759 men and 2,002 women at phase 9 (2007–2009).
The University College London Ethics Committee reviewed and approved the
study, and written informed consent was obtained from each participant at
each phase. Phase 3 is considered the baseline for the purpose of this study,
because it was the ﬁrst clinical examination in which OGTTs were performed.
Participants wereeligible forinclusioninthis study if theywere ofEuropean
descent, had available DNA, and did not have prevalent diabetes at phase 3 (a
total of 4,038 men and 1,505 women). Of 20,215 fasting or 2-h glucose obser-
vation points in these 5,543 individuals, 5,769 observations were excluded
because samples were nonfasting (fasting ,8 h). An additional 1,305 obser-
vations were excluded because they were obtained after a diagnosis of di-
abetes (a total of 627 of 5,543 included individuals [11.3%] developed diabetes
during follow-up) or did not have a contemporary BMI measurement. With
these restrictions, 347 individuals no longer contributed any observations and
were effectively excluded, yielding the maximum study population of 5,196
individuals who contributed a total of 13,141 observation points. The number
of individuals and observation points differs slightly depending upon genotype
information; exact numbers are provided in Supplementary Table ST2. In-
formation for analyses of the fasting and 2-h glucose genetic scores was
available for a total of 4,008 and 3,968 individuals with 10,151 and 9,845 ob-
servation points, respectively.
Measurements
Blood glucose and diabetes. Blood samples at all phases were handled
according to standard protocols. Venous blood was taken after a requested
overnight fast before participants underwent a standard 75-g 2-h OGTT. The
Whitehall II study protocol allowed participants with an afternoon appointment
to have a light breakfast at least 5 h prior to their appointment. For the purpose
of this analysis, samples obtained ,8 h after the last reported meal were
excluded. Glucose samples were drawn into ﬂuoride monovette tubes and
centrifuged on site within 1 h. Blood glucose was measured using the glucose
oxidase method (13) on a YSI model 23A glucose analyzer (YSI, Yellow
Springs, OH; phase 3, mean coefﬁcient of variation 2.9–3.3%) and a YSI model
2300 Stat Plus analyzer (phases 5, 7, and 9, mean coefﬁcient of variation 1.4–
3.1%), as previously described (1). At each phase, diabetes was deﬁned by
World Health Organization criteria based on fasting glucose $7.0 mmol/L or
2-h glucose $11.1 mmol/L (14). Participants reporting doctor-diagnosed di-
abetes or the use of diabetes medications were classiﬁed as having diabetes
regardless of their OGTT results. The date of diabetes diagnosis was assigned
according to the interval method as the midpoint between the ﬁrst visit with
a diabetes diagnosis and the last visit without diabetes.
Genotyping.DNAwasextracted fromwhole-bloodsamplescollected atphase
7( n = 6,311 participants with blood samples attending phase 7 and consenting
to DNA analysis for a total of 6,483 attending phase 7) using magnetic bead
technology (Source Bioscience LifeSciences, Nottingham, U.K.). DNA ex-
traction was successful for 6,156 participants. Genotyping of single nucleotide
polymorphisms (SNPs) associated with fasting and 2-h postload glucose was
carried out using Taqman assays in all participants of European descent who
had DNA available (n = 5,666). Call rates were .96% and duplicates (9%) were
99% concordant. P values for all SNPs were $ 0.04 when testing for deviation
from Hardy-Weinberg equilibrium.
We included 16 SNPs in or near MTNR1B, ADRA2A, CRY2, ADCY5,
SLC2A2, TCF7L2, SLC30A8, FADS1, C2CD4B (previously FAM148B),
DGKB-TMEM195, PROX1, GCK, G6PC2, GLIS3, GCKR,a n dMADD for fast-
ing glucose (10) and GIPR, TCF7L2, GCKR, VPS13C,a n dADCY5 for 2-h
glucose (11). Effect alleles were deﬁned to be the glucose-raising alleles
(Supplementary Table ST2), as previously described (10,11). SNPs in TCF7L2,
GCKR,a n dADCY5 are associated with both fasting and 2-h glucose, with
SNPs in GCKR known to affect fasting and 2-h glucose levels in opposite
directions (reﬂected in the allele coding for the fasting and 2-h glucose GCKR
SNPs rs780094 and rs1260326). For these three loci, different SNPs were identi-
ﬁed in the respective fasting and 2-h GWASs and were genotyped in this study;
however, locus-speciﬁc SNPs are all in high linkage disequilibrium (r
2 . 0.74).
Genetic scores. Genetic scores were calculated separately for fasting and 2-h
glucose. Genetic scores were deﬁned as the additive sum of the number of
glucose-raising alleles for each participant based on SNPs reaching genome-
wide signiﬁcance in combined discovery and replication samples in published
fasting or 2-h glucose GWASs. The mean SNP score (6SD) was 17.0 6 3.0 for
fasting glucose and 4.0 6 1.4 for 2-h glucose. Sensitivity analyses were per-
formed using weighted genetic scores for fasting and 2-h glucose based on
published b-coefﬁcients from replication samples only (10,11), where the sum
of the weights was set to the number of SNPs and the weights were pro-
portional to the estimate of the replication effect size for each SNP.
Other covariates. Information on date of birth and sex was available from the
phase 1 questionnaire. BMI (kg/m
2) was calculated from standardized mea-
surements of weight and height taken at each clinic visit.
Statistical analysis. Statistical analyses were undertaken using SAS version
9.1 (SAS Institute, Cary, NC) and R version 2.11.1. Statistical signiﬁcance was
inferred at a 5% level. Trajectories of fasting and 2-h glucose were estimated
using multilevel models, taking age as the underlying time scale and accounting
for the dependence of measurements within individuals. This method is not
sensitive to missing observation points, and individuals without complete in-
formation for all phases were included in the analyses, assuming that missing is
random, with individuals with one data point contributing to cross-sectional
associations and to group-level trajectories.
We ﬁrst ﬁtted nonparametric curves of individual trajectories and trajec-
tories by tertiles of the fasting and 2-h glucose genetic scores using locally
weighted scatterplot smoother. Individual trajectories of fasting and 2-h glu-
cose were analyzed using mixed models, ﬁtting a random intercept and slope
term for both fasting and 2-h glucose (see Supplementary Methods for more
detail). The overall trajectory and the group trajectories (by SNPs) of fasting
and 2-h glucose were modeled as a ﬁxed intercept and slope term, and results
from these models are presented.
The effect of each SNP was modeled as a continuous variable, where the
effect of having zero, one, or two glucose-raising alleles is assumed to be
additive. Similarly, SNP scores were modeled as continuous variables. Curves
ﬁtted to the trajectories are characterized by their intercept (level of fasting or
2-h glucose) and slope (increase in fasting or 2-h glucose with age), and the
effects ofSNPs (orgenetic score)ontheslopeare testedas SNP(geneticscore)
interactions with age.
All analyses were adjusted for sex and time-varying BMI, except for those
performedto generate plots of changesin fasting and 2-h glucose bypercentiles
of each genetic score, where BMI was assumed to be constant over time for
simplicity. Two- and three-way interactions between age, sex, and BMI were
investigated and excluded from the ﬁnal models because they were non-
signiﬁcant. The time parameter (age) was centered arbitrarily at age ~55 years
for easier interpretation of parameter estimates. We built separate models for
eachfastingand2-hglucoseSNPandforthefastingand2-hglucoseSNPscores.
A detailed model description is included in Supplementary Appendix A.
RESULTS
Population characteristics. Characteristics of partici-
pants included in the analyses at study phase 7 (the phase
of DNA collection), in comparison with those participants
who attended phase 7 but were excluded from analyses
for any of the reasons outlined above, are shown in
Supplementary Table ST1. Those excluded were more likely
to be women (38.5 vs. 26.8%), were on average aged $1.8
years (95% CI 1.5–2.1), had a 0.6 kg/m
2 (0.4–0.9) higher BMI,
and had 0.7 mmol/L (0.6–0.8) higher fasting and 0.6 mmol/L
(0.4–0.7) higher 2-h glucose levels compared with partici-
pants who were eligible and included in this study. All 5,196
participants were born between 1930 and 1952, their ages
ranging from 40 to 78 years during a maximum follow-up of
18 years. Details of genetic variants included in this study
are shown in Supplementary Table ST2.
Population trajectories of fasting and 2-h glucose.
Estimated fasting and 2-h glucose levels across the follow-
up were 5.33 mmol/L (95% CI 5.32–5.35) and 5.84 mmol/L
(5.79–5.89), respectively, for a man aged 55 years with
a BMI of 27 kg/m
2, and 5.10 mmol/L (5.07–5.13) and 5.87
mmol/L (5.79–5.96), respectively, for a woman aged 55
years with a BMI of 27 kg/m
2. Fasting glucose levels in-
creased marginally with increasing age by 0.002 mmol/L
(0.001–0.003) per year of age in models adjusted for sex
and time-varying BMI. In contrast, 2-h glucose levels
showed a more pronounced increase over time, with a rise
of 0.071 mmol/L (0.067–0.074) per year.
Individual and combined associations of common
genetic variants with fasting glucose by age. Signiﬁ-
cant associations with fasting glucose at age 55 years were
observed for 9 of 16 SNPs, with mean per-allele differences
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majority of established fasting glucose loci, in line with the
earlier report (10). Age-dependent analysis suggested that
the association of rs560887 in G6PC2 became stronger
(P = 0.041) with advancing age (Fig. 1, right panel). No
signiﬁcant differences in associations by age were found
for the remainder of fasting glucose loci (Fig. 1, right
panel). Considering joint associations of the 16 fasting
glucose loci, a signiﬁcant difference of 0.029 mmol/L (95%
CI 0.023–0.034) per genetic score point (P = 2.76 3 10
221)
was observed in participants at age 55 years, an associa-
tion that remained constant over time (P value for age
interaction = 0.17; Fig. 1, left and right panels; Fig. 3).
Individual and combined associations of common
genetic variants with 2-h glucose by age. Glucose-
raising alleles of all ﬁve 2-h glucose loci were positively
associated with postload glucose levels at age 55 years,
with effect sizes that were similar to or larger than those
previously reported (11), with variants in GIPR, TCF7L2,
and ADCY5 reaching conventional levels of statistical
signiﬁcance (Fig. 2, left panel). Of ﬁve established loci, the
association of TCF7L2 at age 55 years (0.066 mmol/L [95%
CI 0.001–0.132]; P = 0.046) became signiﬁcantly stronger
with increasing age by 0.012 mmol/L (0.006–0.019) per al-
lele per year (P value for age interaction = 1.1 3 10
24
mmol/L; Fig. 2, right panel). Investigating the combined
associations of all 2-h-glucose loci risk alleles, 2-h glucose
levels were 0.076 mmol/L (0.047–0.105) higher per genetic
score point (P = 3.1 3 10
27); notably, this association
became stronger with increasing age by 0.0059 mmol/L
(0.0031–0.0087) per genetic score point per year (Fig. 2,
left and right panels; P value for age interaction = 3.0 3
10
25), resulting in diverging age trajectories by genetic
score (Fig. 3).
For both fasting and 2-h glucose sensitivity analysis for
the combined effect of all SNPs was performed by calcu-
lating both unweighted and weighted genetic scores sep-
arately, with both scores yielding very similar results.
Associations of changes in BMI with changes in
fasting and 2-h glucose. In models described above,
and including age, sex, genotype score, and time-varying
BMI, changes in BMI over the study period were associ-
ated with increases in 2-h glucose of 0.098 mmol/L (95% CI
0.088–0.108) per kg/m
2 (P value = 3.27 3 10
280), an effect
size that was three times as large compared with that ob-
served for fasting glucose (0.033 mmol/L [0.030–0.037];
P value = 3.92 3 10
277).
DISCUSSION
The effects of aging on trajectories of fasting compared
with 2-h postload glucose differ, with 2-h glucose showing
a steeper age-related rise in nondiabetic individuals than
fasting glucose (1,3,4). Using prospective, repeated measures
FIG. 1. Effect of 16 selected SNPs on fasting glucose levels. Left panel: Mean difference in fasting glucose per risk allele at age 55 years adjusted
for BMI (intercept). Right panel: Mean increase in fasting glucose per risk allele per year of age, over and above the effect at age 55 years (age-
dependent change in effect).
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observational Whitehall II cohort, who were followed for
a maximum of 18 years, we demonstrate for the ﬁrst time
that genetic susceptibility for increased levels of 2-h glu-
cose contributes to the steeper age-related rise of this trait.
Of ﬁve established 2-h glucose loci, common variation in
TCF7L2 showed a signiﬁcant effect and the strongest in-
dividual effect, with an increase in effect of 0.012 mmol/L
per year per glucose-raising allele, which translates into an
additional increase in 2-h glucose levels of 0.49 mmol/L
when aging from 55 to 75 years and comparing partic-
ipants carrying both versus no TCF7L2 risk alleles.
TCF7L2 is the strongest type 2 diabetes gene identiﬁed to
date, with a per-allele odds ratio of ~1.4. Although the
association between variants in TCF7L2 and type 2 di-
abetes was ﬁrst reported in 2006 (15), the exact mecha-
nism by which the identiﬁed variants increase type 2
diabetes risk is still debated (16). Results from this study
suggest that variants in TCF7L2 increase type 2 diabetes
risk via an age-related effect on postload glucose levels,
potentially as a consequence of age-dependent changes in
the multiple effects previously reported for TCF7L2. These
include decreased b-cell mass (17,18), impaired insulin
processing or release (17,19,20), impaired incretin signal-
ing in b-cells (17,19,21), decreased glucagon secretion
(19), and hepatic insulin resistance (19). Interaction effects
of the other four 2-h loci were also positive, but small and
nonsigniﬁcant, and are thus likely to have had a minor
contribution to the age-related effect of the genetic sus-
ceptibility score in comparison with TCF7L2.
Although the effects of risk alleles in or near the 16 loci
associated with fasting glucose combined into a genetic
susceptibility score did not signiﬁcantly change with age
and showed parallel glucose trajectories throughout mid-
dle age by genetic score group, one of the fasting glucose
loci, G6PC2, showed a signiﬁcant increase in its effect
with age. However, the magnitude of the time-dependent
effect was comparatively small (0.002 mmol/L per year per
allele), amounting to an additional increase in fasting glu-
cose levels of 0.08 mmol/L when aging from 55 to 75 years
and comparing participants carrying both versus no
G6PC2 risk alleles. Bonferroni correction for multiple
testing of 23 “independent” tests (including tests for all
fasting [n = 16] and 2-h SNPs [n = 5] plus tests for each
genetic score [n = 2]) resulted in a nonsigniﬁcant in-
teraction term for the age-dependent effect of G6PC2
on fasting glucose levels. In contrast, the corrected age
interactions observed for TCF7L2 (Pcorrected = 2.5 3 10
23)
and the 2-h glucose genetic susceptibility score (Pcorrected =
3.2 3 10
24)r e m a i n e ds i g n i ﬁcant. Although it is arguable
whether individual SNPs and the genetic scores constitute
independent tests, we counted each of the tests sepa-
rately to apply a more stringent statistical correction
and be conservative in our interpretation. However, us-
ing less stringent criteria did not alter our results or
conclusions.
FIG. 2. Effect of ﬁve selected SNPs on 2-h glucose levels. Left panel: Mean difference in 2-h glucose per risk allele at age 55 years and adjusted for
BMI (intercept). Right panel: Mean increase in 2-h glucose per risk allele per year of age, over and above the effect at age 55 years (age-dependent
change in effect).
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GWASs of glycemic traits are small, and large sample sizes
are required to identify effects in individual replication
studies such as Whitehall II, as evidenced by the fact that
we failed to observe signiﬁcant main associations for some
of the weaker established SNPs despite effect sizes that
are comparable to previous meta-analyses. This study is
therefore also likely to be underpowered to observe sig-
niﬁcant interactions with age for small effects; however,
the clinical signiﬁcance of identifying interactions smaller
than those observed in this study may be questionable. For
example, the effect of a difference in one unit of the ge-
netic score for fasting or 2-h glucose observed in this study
is equivalent to the effect of a 1 kg/m
2 difference in BMI or
2 additional years of age in the case of 2-h glucose; in
comparison, the age-dependent effect of the 2-h glucose
genetic score amounts to an additional 0.06 kg/m
2 or 1.6
months of aging per year. Future studies of similar size are
warranted to replicate our ﬁndings in an independent
setting, although few studies have prospective data with
repeated OGTTs over a follow-up of 18 years available.
The observation that fasting glucose levels do not show
the steep age-related rise of postload glucose levels may
point toward a smaller inﬂuence of environmental factors
on this trait compared with 2-h glucose levels, with
a number of previous studies showing a larger nongenetic
component to variance in 2-h glucose levels compared
with fasting glucose (22,23), although it is important to
note that the magnitude of genetic and nongenetic con-
tributions to fasting and 2-h glucose levels can vary by the
population studied. However, in support of this, the
greater number of loci identiﬁed for fasting versus 2-h
FIG. 3. Estimated mean fasting and 2-h glucose levels for the 25th (red), 50th (green), and 75th (blue) percentiles of the respective fasting (left
panels) or 2-h (right panels) genetic scores for men with a BMI of 23 kg/m
2 (A), men with a BMI of 27 kg/m
2 (B), women with a BMI of 23 kg/m
2
(C), and women with a BMI of 27 kg/m
2 (D). Values of the score are 17, 19, and 20 for fasting glucose and 3, 4, and 5 for 2-h glucose for the 25th,
50th, and 75th percentiles, respectively.
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although the somewhat smaller GWAS sample size and the
greater measurement error and SD of 2-h glucose may also
contribute (10,11). Taken together with the fact that large
differences in fasting glucose according to presence or
absence of fasting glucose-raising alleles have been dem-
onstrated as early as young childhood for the earliest
published fasting glucose loci (24), this suggests a model in
which genetic inﬂuences on fasting glucose levels are evi-
dent early in life and contribute to long-term differences in
glucose trajectories that remain constant with increasing
age. Few studies (7,25,26) have published results based on
longitudinal data. These reported effects of rs1799884 in
GCK on changes in fasting glucose cross-sectionally (25),
without evidence of differences in effects by age or over
time (26). Lyssenko et al. (7) also showed that carriers
of the fasting glucose–raising G allele in MTNR1B
(rs10830963) had higher glucose levels and lower insulin
secretion at baseline as well as 7 years later in the Botnia
study. Likewise, during 24-years of follow-up in the Malmö
Preventive Project, glucose levels in GG homozygotes rose
by only 0.05 mmol/L, with similar small differences in the
other genotype groups, emphasizing the stable trajectories
of fasting glucose with age (7).
The key environmental factors contributing to the rise in
2-h glucose with age are unclear, but previous studies have
suggested that increases in sedentary behavior and adi-
posity may be key determinants (27). Our results show an
effect of changes in BMI over the study period on 2-h
glucose that was three times as large compared with that
observed for fasting glucose, in line with a stronger in-
ﬂuence of age-related lifestyle behavioral factors on post-
challenge glucose. However, in the current study the
effects of genetic variants on changes in 2-h glucose over
time were not explained by changes in BMI over the same
time, although other measures of adiposity may be more
important but have not yet been investigated.
The results presented here are the ﬁrst to show that
common genetic variants may contribute to the age-related
rise in postload glucose in nondiabetic individuals. As for
the example of TCF7L2, effects could be mediated by
defects in b-cell function and changes in insulin secretion,
rather than inﬂuences on insulin sensitivity because the
majority of studies investigating effects of TCF7L2 vari-
ants report effects on insulin secretion/processing, with
the few studies showing defects associated with insulin
action yet to be replicated (16). An insulin secretory defect
leading to a deterioration of b-cell function through hy-
perglycemia and b-cell glucotoxicity may contribute to the
age-dependent increase in 2-h glucose levels observed in
this study.
Genetic variants included in this study were recently
discovered based on meta-analyses of cross-sectional
GWASs. Using multilevel models, including prospective,
observational data from 5,196 participants and 13,141
OGTTs, this is the ﬁrst study to investigate differences in
the effects of these recently identiﬁed common genetic
variants on long-term glucose levels in nondiabetic indi-
viduals. Our results suggest that participants’ age may be
an important contributor to the observed heterogeneity
in effects between different studies included in earlier
meta-analyses, particularly for 2-h glucose, and that age-
stratiﬁed analyses may be more appropriate than in-
vestigating average age-adjusted effects.
We raise caution against using our results for the pre-
diction of individual glucose levels. The residual intra- and
interindividual variation in fasting and 2-h glucose after
accounting for the genetic effects and their interaction
with age is still considerable. Consequently, any individual
glucose prediction based solely on genetic and age in-
formation will fall short of predictions based on models
that account for a wider set of established determinants.
Also, results from this study of white, London-based civil
servants are not necessarily representative of the general
population. Although effect estimates of genetic variants
were similar in this study compared with previous studies,
lifestyle and associated behaviors, including factors asso-
ciated with aging, are likely to be different in this occu-
pational cohort, which on average is healthier and socially
advantaged compared with the general population (12).
We observed some differences when comparing the char-
acteristics of participants attending study phase 7 (when
DNA was collected) who were included versus excluded in
this study. However, to bias our results, these differences
would have to be differential with regard to genotype,
which is unlikely to be the case. In addition, given our
exclusion criteria (nonfasting status, prevalent diabetes)
some differences between included and excluded partici-
pants are to be expected. Our analysis includes individuals
who did not have glucose measured at all time points, and
this assumes that missing occurs at random. Again, we
have no reason to believe that individuals were selectively
lost to follow-up based on their genotype.
Our observation of signiﬁcant differences in effects of
glycemic loci with age suggest that the same may be true
for any number of variants discovered in cross-sectional
GWASs. Whether the time-dependent effect of any variant
has an important inﬂuence on the time course of the
phenotype it is associated with will be dependent upon the
magnitude of the effect and its potential modiﬁcation by
other risk factors. In addition to inﬂuencing the time
course of phenotypes, time-dependent effects of variants
could also have clinical relevance, as is suggested here for
TCF7L2, with the time-dependent increases in 2-h glucose
observed with this variant potentially contributing to its
association with increased type 2 diabetes risk.
Although individual effects of common genetic loci in-
cluded in this study are small, differences in glucose levels
between individuals at low and high genetic risk amount to
~1 SD when considering the combined effects of all known
loci in a weighted score using data in our own study; this
result is identical to that reported in the MAGIC study of
adults (10). In addition, effects of fasting glucose loci have
been shown to be evident from early childhood, and,
hence, differences in glucose levels and associated meta-
bolic consequences appear to start at an early age. The
current study extends these ﬁndings and shows that in
addition to existing differences in average glycemia be-
tween individuals at high and low genetic risk at a particular
age, differences attributed to common genetic variation
may become more pronounced at higher ages for 2-h
glucose.
In conclusion, our results suggest that associations be-
tween common genetic variants and fasting glucose are
constant over time, in line with stable age trajectories of
fasting glucose in nondiabetic individuals. We propose
a model in which an individual’s fasting glucose set point is
determined early in life by combinations of genetic vari-
ants with age-independent effects, resulting in relatively
stable trajectories of fasting glucose over the life course. In
contrast, genetic effects on 2-h glucose appear to depend
on age, such that differences in 2-h glucose per additional
VARIANTS AND FASTING AND POSTLOAD GLUCOSE
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carriers of risk alleles in TCF7L2. Our ﬁndings suggest that
the effects of age or related environmental factors need to
be taken into account when studying genetic inﬂuences on
2-h glucose levels and that differences in participants’ ages
may contribute to heterogeneity in effects of postload
glucose loci between studies.
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